Status:
COMPLETED
Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism
Lead Sponsor:
The Second Hospital of Hebei Medical University
Conditions:
Acute Ischemic Stroke
Abnormal Glucose Metabolism
Eligibility:
All Genders
18-75 years
Brief Summary
Urinary kallidinogenase may assist recovery acute ischemic stroke. This study evaluated the impact of urinary kallidinogenase on NIHSS score, modified Rankin scale (mRS) score and fasting glucose leve...
Detailed Description
Patients with AIS and abnormal glucose metabolism were enrolled in this prospective cohort study and divided into two groups. The HUK group were treated with urinary kallidinogenase and standard treat...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Aged 18-75 years (male or female)
- Patients were admitted to hospital within 72h of stroke onset
- Diagnosis of acute ischemic stroke according to the criteria stated in the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China (2010), and patients were confirmed as acute ischemic cerebrovascular disease by head computed tomography (CT) or magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI)
- NIHSS score ranged from 3-21 points
- Patients were previously diagnosed with type 2 diabetes, in which they were in line with the 2006 WHO diagnostic criteria for diabetes, or they had fasting blood glucose of 6.1-6.9mmol/L and glycosylated hemoglobin (HbA1C) of\>6.1%
- Patients could cooperate with the test and evaluation of relevant indicators in the trial.
- Exclusion criteria:
- Pregnant or lactating women
- Patients with severe heart, liver and kidney dysfunction
- Patients with a history of cerebrovascular disease and who still suffered from serious neurological dysfunction that had an influence on the trial
- Patients with physical disabilities, joint deformities or muscle lesions
- Patients were confirmed with intracranial hemorrhage by CT
- Patients were allergic to the study drug
- Patients suffering from severe systemic infection
- Patients who had participated in other clinical trials within 1 month
- For any reason, the researchers believed that the subject was unlikely to complete the study (such as cerebral infarction caused by cerebral embolism, intracranial arteritis, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and moyamoya disease; patients undergoing thrombolysis or thrombectomy after admission; patients and their families were unable to cooperate with follow-up.)
Exclusion
Key Trial Info
Start Date :
December 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT04020666
Start Date
December 1 2016
End Date
October 1 2017
Last Update
July 16 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.